Solriamfetol offers hope for excessive daytime sleepiness in OSA
The dopamine-norepinephrine reuptake inhibitor solriamfetol helps reduce excessive daytime sleepiness in patients with obstructive sleep apnoea (OSA), without compromising primary OSA treatment, as shown in a study.